Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 6/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11026652 | 0.85 | KMT2A (0.58) | KMT2AALDH1A1DRD3HPGDHSD17B10 | |
| Naldixic Acid SCHEMBL10330758 | 0.85 | DRD3 (0.64) | KMT2AALDH1A1DRD3HPGDHSD17B10 | |
| SCHEMBL10330761 | 0.84 | ALDH1A1 (0.66) | KMT2AALDH1A1DRD3HPGDHSD17B10 | |
| SCHEMBL10330793 | 0.82 | ALDH1A1 (0.56) | KMT2AALDH1A1DRD3HPGDHSD17B10 | |
| SCHEMBL11404899 | 0.82 | KMT2A (0.43) | KMT2AALDH1A1DRD3HPGDHSD17B10 | |
| SCHEMBL11552924 | 0.81 | DRD3 (0.52) | KMT2AALDH1A1DRD3HPGDHSD17B10 | |
| SCHEMBL5372335 | 0.81 | KMT2A (0.53) | KMT2AALDH1A1HPGDHSD17B10KDM4E | |
| SCHEMBL9318038 | 0.81 | KMT2A (0.52) | KMT2AALDH1A1DRD3HPGDHSD17B10 | |
| SCHEMBL11390473 | 0.80 | ALDH1A1 (0.77) | KMT2AALDH1A1DRD3HPGDHSD17B10 | |
| SCHEMBL13007994 | 0.80 | DRD3 (0.61) | KMT2AALDH1A1DRD3HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222407-B2 | Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222407-B2 | Mutilin derivative having heterocyclic aromatic ring carboxylic acid structure in substituent at 14-position | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100197909-A1 | MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197909-A1 | MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197909-A1 | MUTILIN DERIVATIVE HAVING HETEROCYCLIC AROMATIC RING CARBOXYLIC ACID STRUCTURE IN SUBTITUENT AT 14-POSITION | PELP1, MLN, SND1 | KMT2A 2975/4885ALDH1A1 1380/4885DRD3 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.